Lantern Pharma Prepares 2026 Trial For Rare Pediatric Brain Cancer After FDA Guidance

Dallas-based biopharma company Lantern Pharma is gearing up for a Phase 1b/2 clinical trial in early 2026 of its candidate LP-184 (STAR-001) for rare pediatric central nervous system cancers, including atypical teratoid rhabdoid tumors, following favourable feedback from the U.S. Food & Drug Administration. The investigation will evaluate LP-184 in combination with spironolactone and is supported by Rare Pediatric Disease and Orphan Drug designations, as the company leverages its AI-driven RADR platform to identify optimized treatment combinations.